Defactinib

Drug Profile

Defactinib

Alternative Names: PF-04554878; PF-4554878; VS-6063

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; Verastem; Washington University
  • Class Antineoplastics; Benzamides; Pyrazines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma; Non-small cell lung cancer
  • Phase I Cancer; Pancreatic cancer; Solid tumours
  • Preclinical Breast cancer
  • No development reported Ovarian cancer

Most Recent Events

  • 30 Sep 2016 Verastem, Merck Sharpe & Dohme and Cancer Research UK to co-develop defactinib and pembrolizumab for Mesothelioma, Non-small cell lung and Pancreatic cancer
  • 30 Sep 2016 Verastem and MSD plans a phase Ib/IIa trial for Cancer in the UK
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy, Late-stage disease) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top